TRAIL receptors are particularly noteworthy in cancer research because many cancer cells exhibit increased sensitivity to TRAIL-induced apoptosis. This property has spurred the development of TRAIL-based therapies, including recombinant TRAIL and agonistic antibodies targeting DR4 and DR5. These therapies aim to selectively induce apoptosis in cancer cells, offering a novel approach to cancer treatment with reduced toxicity compared to traditional chemotherapeutic agents.
